Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1983-12-17
|
pubmed:abstractText |
Sulmazol (AR-L 115 BS) is a new inotropic drug which has arterial and venous vasodilating properties. We used it in seven patients with severe refractory heart failure to determine the effective plasma concentration levels and the most effective bolus dose on haemodynamics. The haemodynamic monitoring included a Swan-Ganz catheter in the pulmonary artery and a radial catheter. Haemodynamic measurements and plasma concentration determinations were performed before sulmazol injection and at 5, 10 and 30 min after a bolus 0.25, 0.50, 0.75 mg/kg. We observed a gradual increase in cardiac index and decrease in pulmonary wedge pressure when plasma concentration levels rose but the beneficial effects were mainly observed for sulmazol plasma concentrations above 1 microgram/ml. A bolus injection of 0.75 mg/kg was effective in all cases: a significant increase of cardiac index (1.9 to 2.5 1 min-1 m-2; P less than 0.001) and a significant decrease in pulmonary wedge pressure (30 to 25 mm Hg; P less than 0.005) and right atrial pressure (13 to 10 mm Hg, P less than 0.01) were observed. In these patients sulmazol improved the severely deteriorated left ventricular function without affecting heart rate and blood pressure.
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/6626424-495512,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6626424-6177927,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6626424-6177937,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6626424-6214330,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6626424-7148647,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6626424-7195209,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6626424-7195235,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6626424-7217320,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6626424-7357717,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6626424-7362714,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6626424-7438412
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0306-5251
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
16
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
313-8
|
pubmed:dateRevised |
2009-11-18
|
pubmed:meshHeading |
pubmed-meshheading:6626424-Aged,
pubmed-meshheading:6626424-Cardiotonic Agents,
pubmed-meshheading:6626424-Dose-Response Relationship, Drug,
pubmed-meshheading:6626424-Heart Failure,
pubmed-meshheading:6626424-Hemodynamics,
pubmed-meshheading:6626424-Humans,
pubmed-meshheading:6626424-Imidazoles,
pubmed-meshheading:6626424-Male,
pubmed-meshheading:6626424-Middle Aged
|
pubmed:year |
1983
|
pubmed:articleTitle |
The effective plasma concentrations of sulmazol (AR-L 115 BS) on haemodynamics in chronic heart failure.
|
pubmed:publicationType |
Journal Article
|